ArticleHaematologica2026
The landmark contribution by Erik von Willebrand.
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Perioperative hemostasis management in patients with von Willebrand disease undergoing cardiac surgery: A scoping review.JTCVS open · 2026Article
- Von Willebrand disease: A century of progress.Research and practice in thrombosis and haemostasis · 2026Review
- Introduction to the Review Series. A century after Erik von Willebrand.Haematologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One hundred years ago Professor Erik von Willebrand, working at the Deaconess Hospital in Helsinki, Finland, published his landmark paper on hereditary pseudohemophilia (the original paper, in Swedish, was entitled Hereditär pseudohemofili and was published in Finska Läkaresällskapets Handlingar). In 1924, a 5-year-old girl named Hjördis, living in Föglö in the Åland Island archipelago, was brought to Erik von Willebrand's attention; his investigations of a large family living in the Åland Islands emerged in the 1926 publication in which a new hereditary bleeding disorder, distinct from classic hemophilia, was described. The index case was the ninth of 11 siblings of whom three had already bled to death. Hjördis herself had a history of serious bleeding, including nose bleeds, hematomas, anemia and, also, an ankle bleed. At the age of 14 years, she drastically bled to death during her fourth menstruation. Erik von Willebrand came close with his interpretation of the disorder, but it took several decades until other investigators could fully elucidate the pathophysiology underlying the bleeding diathesis which nowadays is known as von Willebrand disease. The index case had the most severe subtype 3. The structure, function and genetics of the factor named von Willebrand factor have now been revealed and the symptoms, epidemiology and treatment of the disorder thoroughly studied. The pioneering and visionary work of Erik von Willebrand, combining laboratory methods and clinical sharpness, set the stage for improving the lives of numerous people suffering from a generalized bleeding tendency or even life-threatening bleeds due to this most common hereditary bleeding disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.